With Medivation, Pfizer Sees A Chance For More Combinations

Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.

Pfizer Inc. is relying on future growth of the prostate cancer therapy Xtandi (enzalutamide) to justify the $14bn price it will pay to buy Medivation Inc., but two pipeline products and the potential for developing drugs in combination across pipelines could be longer term growth drivers.

“Medivation’s pipeline and innovative assets, including a PARP inhibitor and an immuno-oncology agent, play in the most attractive areas in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

13 Jun 2025

• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

12 Jun 2025

• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

12 Jun 2025

• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.